Galera Therapeutics Inc expected to post a loss of 75  cents a share - Earnings Preview

Galera Therapeutics

07/03/2022 11:02

* Galera Therapeutics Inc  GRTX.OQ   GRTX.O  is expected
to show
no change in quarterly revenue when it reports  results on March
9 (estimated). 
    * ​Refinitiv's mean analyst estimate for Galera Therapeutics
Inc
is for a loss of 75 cents per share. For the same quarter last
year, the company reported a loss of 80 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Galera
Therapeutics Inc is $16​, about 86.6% above​ its last closing
price of $2.14. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.78       -0.77      -0.86     Missed  -12.4
 Jun. 30 2021  -0.81       -0.83      -0.88     Missed  -6.2
 Mar. 31 2021  -0.84       -0.83      -0.75     Beat    9.7​
 Dec. 31 2020  -0.68       -0.71      -0.80     Missed  -13
 ​​Sep.        -0.77       -0.77      -0.69     Beat    10.5
 30 2020                                                
 Jun. 30 2020  -0.76       -0.76      -0.75     Beat    1.1​
 Mar. 31 2020  -0.70       -0.70      -0.74     Missed  -6.3
 Dec. 31 2019  -0.54       -0.55      -1.31     Missed  -137.7
 This summary was machine generated March 7 at 11:02 GMT.  All
figures in US dollars  unless otherwise stated